Omeros Corporation reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated $9.9 million in product sales from its newly launched drug, YARTEMLEA, which received FDA approval in December 2025 for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. This marks a notable increase from zero revenue in the same period last year. The company’s total costs and expenses for the quarter were $27.3 million, down from $34.9 million a year earlier, primarily due to reduced research and development expenses following the sale of its MASP-3 inhibitor, zaltenibart, to Novo Nordisk.
Omeros reported a net income of $56.1 million for the quarter, a substantial turnaround from a net loss of $33.5 million in the prior year. This improvement was largely driven by a $73.1 million gain from the remeasurement of embedded derivatives related to its 2029 convertible notes. The company’s accumulated deficit decreased to $857.6 million from $913.7 million at the end of 2025, reflecting the positive impact of its recent financial activities.
In terms of operational metrics, Omeros has begun commercial distribution of YARTEMLEA, with 30 unique accounts ordering the product by the end of March 2026. The company is actively engaging with 175 stem-cell transplant centers across the U.S. to promote the drug, which is the first approved inhibitor of the lectin pathway of complement. The company’s workforce has also expanded, with a focus on building its commercial organization to support the launch of YARTEMLEA.
Looking ahead, Omeros expects to increase its research and development expenditures in the second quarter of 2026, particularly for its YARTEMLEA and OncotoX-AML programs. The company has $135.3 million in cash, cash equivalents, and short-term investments as of March 31, 2026, which it believes will be sufficient to fund operations for over 12 months. Omeros is also exploring additional financing options, including potential equity offerings and strategic partnerships, to support its ongoing development initiatives.
About OMEROS CORP
Omeros Corporation is a clinical-stage biopharmaceutical company developing small-molecule and protein therapeutics targeting immune-related diseases, including complement-mediated disorders, cancers, and addiction. Its lead programs focus on complement system inhibitors, notably narsoplimab for thrombotic microangiopathies, and zaltenibart for rare blood and kidney diseases. The company owns extensive intellectual property and retains worldwide rights for its innovative biologics and small-molecule drug candidates.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.